News & Updates
Filter by Specialty:
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
27 Nov 2022
CT angiography may increase potential EVT recipients for acute ischaemic stroke
Using collateral flow findings, as seen on computed tomographic (CT) angiography, may widen the population who can undergo late endovascular treatment (EVT) for acute ischaemic stroke (AIS), according to findings of the MR CLEAN-LATE trial.
CT angiography may increase potential EVT recipients for acute ischaemic stroke
27 Nov 2022
Trust improves uptake of adjuvant endocrine therapy in breast cancer
Breast cancer patients with a more trustful bond with their physicians appear to be more open to taking adjuvant endocrine therapy (AET) and show lower concerns regarding the treatment, a recent study has found.
Trust improves uptake of adjuvant endocrine therapy in breast cancer
27 Nov 2022
Alprazolam safe, effective for controlling seizures
The use of alprazolam leads to rapid termination of seizures in patients with focal and/or generalized epilepsy treated in an inpatient setting, according to the results of the phase II study ENGAGE-E-001.
Alprazolam safe, effective for controlling seizures
26 Nov 2022
Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
Although the incidence of myocarditis or pericarditis following mRNA COVID-19 vaccination is low, a two- to threefold higher likelihood is seen among individuals who received mRNA-1273 compared to BNT162b2 vaccine, reveals a study.